𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience

✍ Scribed by Karen S. Blesch; Ronald Gieschke; Yuko Tsukamoto; Bruno G. Reigner; Hans U. Burger; Jean-Louis Steimer

Book ID
110437866
Publisher
Springer US
Year
2003
Tongue
English
Weight
405 KB
Volume
21
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pharmacokinetic-pharmacodynamic modellin
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs – method development and application to magnesium in sheep
✍ Richard N Upton; Guy L Ludbrook πŸ“‚ Article πŸ“… 2005 πŸ› BioMed Central 🌐 English βš– 737 KB

## Background There have been few reports of pharmacokinetic models that have been linked to models of the cardiovascular system. Such models could predict the cardiovascular effects of a drug under a variety of circumstances. Limiting factors may be the lack of a suitably simple cardiovascular mod

Utility of a physiologically–based pharm
Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4